

Evaluation of Oral Minoxidil in the Treatment of Alopecia Areata

Virginia C. Fiedler-Weiss, MD; Jean Rumsfield, PharmD; Cunera M. Buys, MS; Dennis P. West, MS; Andrea Wendrow

• A dose-response effect has previously been demonstrated in topical minoxidil treatment of alopecia areata. Limitations in minoxidil solubility and percutaneous absorption have impaired the development of more effective topical therapy. Oral minoxidil (5 mg every 12 hours), a dose demonstrated to be relatively well tolerated if a 2-g sodium diet is strictly followed, was given to 65 patients with severe, treatment-resistant alopecia areata in an attempt to bypass the limitations of topical treatment and increase efficacy. Although hair regrowth progressed more rapidly and was more extensive with oral than topical 5% minoxidil, cosmetic response was seen only in 18% of the patients. Neither serum nor tissue levels of minoxidil correlated with response. These findings suggest that improved preparations of topical minoxidil, when used as a single therapeutic agent, are unlikely to be cosmetically effective in the majority of patients with severe alopecia areata.

(*Arch Dermatol* 1987;123:1488-1490)

Topical minoxidil has been shown to elicit hair regrowth in alopecia areata (AA).^{1,3} The data suggest a dose-response effect for topical minoxidil (1% vs 5%) treatment of AA.² Despite these encouraging results, cosmetic regrowth was ultimately achieved only in six (13%) of 47 patients with severe AA who were treated with topical 5% minoxidil.³ Patients who achieved cosmetically acceptable regrowth showed a steady increase in hair growth at

each visit. The majority of patients discontinued 5% minoxidil at the termination of the protocol because of lack of significant progress in the preceding three to six months.³

Thus far, 5% is the approximate maximum concentration of minoxidil that can be formulated for topical use. The possibility that higher tissue levels and greater efficacy might be achieved with oral minoxidil remains to be examined. We report in this study our results of oral minoxidil treatment of severe AA.

PATIENTS AND METHODS

After giving signed, informed consent, 65 patients were entered into a study to determine safety and efficacy of low-dose (5 mg every 12 hours) oral minoxidil in the treatment of severe AA. Patients included were 27 men and 38 women, ranging in age from 13 to 55 years (mean, 31 years). The mean duration of the current episode of hair loss was 5.9 years (range, one to 26 years). Extent of scalp hair loss at baseline was 75% to 100% in 44 (68%) patients, 25% to 74% in 19 (29%), and 0% to 24% in two (3%).

Before enrollment in the study, patients were evaluated by history, physical examination, and electrocardiogram to exclude those with hypertension, cardiovascular disease, or severe systemic illness. Any patient who was judged to be noncompliant was also excluded. Patients were seen at baseline, one month, and every three months thereafter.

Table 1.—Comparison of Response to Minoxidil*
(Topical 5%† vs Oral‡)

Hair Loss, %	Begin Topical, No. (%)	End Topical- Begin Oral, No. (%)	Oral, No. (%)
0 to 24	0 . . .	1 (3)	11 (32)
25 to 74	7 (21)	10 (29)	7 (21)
75 to 99	12 (35)	16 (47)	11 (32)
100	15 (44)	7 (21)	5 (15)

* Thirty-four patients treated in both studies.

† Topical 5% minoxidil applied every 12 hours for 12 to 15 months.



‡ Oral minoxidil, 5 mg every 12 hours for six months.

Accepted for publication May 7, 1987.

From the Departments of Dermatology (Drs Fiedler-Weiss, Rumsfield, and Ms Buys) and Pharmacy Practice (Mr West and Ms Wendrow), the University of Illinois at Chicago.

Presented in part at the Annual Meeting of the American Academy of Dermatology, New Orleans, Dec 8, 1986.

Reprint requests to University of Illinois College of Medicine at Chicago, Department of Dermatology (M/C 624), PO Box 6998, Chicago, IL 60680 (Dr Fiedler-Weiss).



Left, Patient after 15 months of topical 5% minoxidil (1 mL every 12 hours) treatment.
Right, Same patient after four months of oral minoxidil (5 mg every 12 hours) treatment.

At each visit, pulse, blood pressure, and weight were monitored; cardiac auscultation was performed; evidence of edema, headaches, depression, or lethargy was sought. Laboratory studies obtained at each visit included a complete blood cell count, serum electrolyte values, liver enzyme levels, serum creatinine concentration, and gross and microscopic urinalysis. Electrocardiograms were obtained at baseline and every six months. Echocardiograms were obtained at baseline, six months, and 12 months, and thereafter only as indicated by physical examination or electrocardiographic changes. Scalp biopsies were performed at baseline and at six months. Serum minoxidil levels were monitored at each visit for the first 12 to 18 months of treatment. Minoxidil assays of serum and scalp biopsy tissue were performed as previously described.⁴

Photographic documentation was obtained at each visit. Cosmetic response was defined as sufficient terminal hair regrowth such that the patient no longer needed a wig or cap to conceal any residual alopecia. Fair response was defined as extensive, but not cosmetic, regrowth. Slight response was defined as sparse terminal hair regrowth. Nonresponse was defined as vellus or no regrowth.

Strict adherence to a 2-g sodium diet was required for the duration of treatment. Minoxidil, 5 mg every 12 hours, was prescribed. This dosage was chosen, in part, because higher doses are not uniformly well tolerated. The mean

Hours After Dose	Serum Level† (No. of Determinations)	Tissue Level‡ (No. of Determinations)
1	64.0 (6)	...
2	43.5 (47)	98.1 (6)
3	29.5 (63)	137.9 (7)
4	14.8 (43)	14.4 (3)
5	15.2 (25)	60.0 (1)
6	4.5 (1)	...
7
8	0.7 (1)	...
9	2.8 (3)	...
10	0.0 (2)	5.0 (1)
11	0.6 (2)	...
12	1.3 (6)	117.5 (1)

*Minoxidil dose, 5 mg administered orally every 12 hours.

†Mean values, nanograms per milliliter.

‡Mean values (nanograms per gram) obtained from scalp biopsy tissues after six months of chronic treatment.

duration of treatment was 53 weeks (range, 20 to 115 weeks).

Thirty-four patients were treated in a previous study with topical 5% minoxidil. They had experienced either no response to treatment or no additional response in the

preceding three to six months. These patients were subsequently enrolled in the present study with oral minoxidil.

RESULTS

Response to oral minoxidil was seen in 52 (80%) of the 65 patients, in 21 (100%) of 21 patients with baseline scalp hair loss less than 75%, and in 31 (70%) of 44 patients with baseline scalp hair loss greater than or equal to 75%. Cosmetic response was seen in 12 (18%) of the 65 patients, in eight (38%) of 21 patients with less than 75% scalp hair loss, and in four (9%) of 44 patients with greater than or equal to 75% scalp hair loss. Cosmetic regrowth was maintained during treatment in all 12 patients, although minor episodes of hair loss occurred in some.

Mean time to response, when present, was 9.3 weeks (range, four to 32 weeks). Mean time to cosmetic response was 34.8 weeks (range, 12 to 61 weeks). Duration of the current episode of hair loss for responders ranged from one to 23 years (mean, 5.5 years); for cosmetic responders it ranged from one to 17 years (mean, 5.8 years); and for nonresponders it ranged from one to 26 years (mean, 7.5 years). Duration of the current episode did not correlate with response.

Data for the 34 patients treated sequentially with topical 5% minoxidil followed by oral minoxidil are found in Table 1. Hair regrowth with oral minoxidil was more rapid and more extensive than it was with topical 5% minoxidil (Figure).

Maximum serum levels of minoxidil were found at one hour after the oral dose. Serum levels were in the negligible range after six hours (Table 2). Maximum tissue levels of minoxidil apparently occur at about three hours (Table 2). Serum and tissue levels showed no correlation with each other or with response to treatment. The mean tissue level for fair and cosmetic responders was 88.01 ng/g of tissue vs 99.90 ng/g of tissue for slight and nonresponders.

Side effects of oral minoxidil were sodium and fluid retention when the 2-g sodium diet was not strictly adhered to; occasional episodes of headaches, depression, or lethargy in women; occasional episodes of palpitations or tachycardia after ingestion of caffeine, alcohol, or decongestants; and facial hypertrichosis in 11 (17%) of the 65 patients.

Thirty-three patients discontinued taking oral minoxidil, 19 because of lack of efficacy and 14 for personal reasons. Seven of these patients reported onset of hair loss within two to eight weeks after discontinuation of treatment.

COMMENT

Oral minoxidil and topical 5% minoxidil produced similar percentages of responders.³ The mean time to regrowth was similar in both studies.² Comparison of the 34 patients who were treated in both studies shows, however, that hair regrowth progressed more rapidly and was more extensive with oral than with topical 5% minoxidil. Cosmetic response was enhanced with oral minoxidil (12/65 [18%]) vs topical 5% minoxidil (6/47 [13%]).³ The mean time to a cosmetic response was also shortened with oral (34.8 weeks [range, 12 to 61 weeks]) vs topical 5% minoxidil (62 weeks [range, 16 to 158 weeks]).³ As in previous studies with topical 1% and 5% minoxidil,^{1,2} the duration of the current episode of hair loss did not correlate with the response or cosmetic response to oral minoxidil.

Peak serum levels were markedly higher with oral vs topical minoxidil treatment.^{1,2} Serum levels after chronic application of topical 5% minoxidil were found to be low (mean, 2.1 ng/mL)² and relatively constant over 24 hours following application.⁵ After an oral dose of minoxidil (5 mg), a peak mean serum level of 64 ng/mL was obtained at one hour; after six hours, serum levels were low. Serum levels following treatment with oral minoxidil did not correlate with tissue levels or with response. The serum levels obtained in this study seem to correlate with side effects noted. In this study, no side effects were serious enough to require discontinuation of minoxidil.

Topical minoxidil slowly penetrates whole skin; the stratum corneum represents over 99% of the total barrier to minoxidil diffusion.⁶ Oral minoxidil, at a dose demonstrated to be relatively well tolerated, was used in an attempt to bypass the barrier to percutaneous absorption and the limitations of minoxidil solubility. Although efficacy was enhanced, only 18% of the patients achieved a cosmetically meaningful response. Mean tissue levels of minoxidil were similar for fair and cosmetic responders vs slight and nonresponders. These data suggest that even if topical minoxidil preparations are improved such that absorption and solubility limitations are overcome, minoxidil as a single therapeutic agent is expected to be cosmetically effective only in a minority of patients with severe AA.

This study was supported in part by a grant from The Upjohn Co, Kalamazoo, Mich.

The authors wish to thank Lawrence K. Oliver, PhD, of The Upjohn Co, Kalamazoo, Mich, for performing the minoxidil assays and Bobbi Calloway for her secretarial assistance.

References

1. Weiss VC, West DP, Fu TS, et al: Alopecia areata treated with topical minoxidil. *Arch Dermatol* 1984;120:457-463.
2. Fiedler-Weiss VC, West DP, Buys CM, et al: Topical minoxidil dose-response effect in alopecia areata. *Arch Dermatol* 1986;122:180-182.
3. Fiedler-Weiss VC: Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. *J Am Acad Dermatol* 1987; 16:745-748.
4. Royer ME, Ko H, Gilbertson TJ, et al: Radioimmunoassay of minoxidil in serum. *J Pharm Sci* 1977;66:1266-1269.
5. Fiedler-Weiss VC: Minoxidil. *Dermatol Clin*, in press.
6. Stehle RG, Ho NFH, Grady RK, et al: In vitro percutaneous absorption of minoxidil and characterization of metabolic properties of hairless mouse skin, abstracted. *Pharm Res* 1986; 3(suppl):72S.